Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK

Endocrine

Volumn 53, Issue 3, 2016, Pages 701-709

  Du, Jing ^a   Zhang, Mingliang ^a   Lu, Junxi ^a   Zhang, Xueli ^a   Xiong, Qin ^a   Xu, Yiting ^a   Bao, Yuqian ^a   Jia, Weiping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

GPRC6A; JNK; Nonalcoholic fatty liver disease; Nrf2; Osteocalcin

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; OSTEOCALCIN; PROTEIN GPRC6A; RECEPTOR; RECOMBINANT DECARBOXYLATE OSTEOCALCIN; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLUCOSE; NFE2L2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID DIET; LIVER INJURY; LIVER PROTECTION; MALE; MORPHOMETRICS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATION REDUCTION REACTION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CATALASE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GLUCOSE; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER; MALE; MALONDIALDEHYDE; MAP KINASE SIGNALING SYSTEM; MICE; NF-E2-RELATED FACTOR 2; NON-ALCOHOLIC FATTY LIVER DISEASE; OSTEOCALCIN; OXIDATION-REDUCTION; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 84961215323     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-016-0926-5     Document Type: Article

References (35)

1. N.K. Lee, H. Sowa, E. Hinoi, M. Ferron, J.D. Ahn, C. Confavreux, R. Dacquin, P.J. Mee, M.D. McKee, D.Y. Jung, Z. Zhang, J.K. Kim, F. Mauvais-Jarvis, P. Ducy, G. Karsenty, Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456–469 (2007)
2. M. Ferron, J. Lacombe, Regulation of energy metabolism by the skeleton: osteocalcin and beyond. Arch. Biochem. Biophys. 561, 137–146 (2014)
3. F. Szalay, P. Lakatos, J. Németh, M. Abonyi, B. Büki, G. Tarján, I. Holló, Decreased serum osteocalcin level in non-alcoholic and alcoholic chronic liver diseases. Orv. Hetil. 132, 1301–1305 (1991)
4. Y. Yilmaz, R. Kurt, F. Eren, N. Imeryuz, Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. Scand. J. Clin. Lab. Invest. 71, 631–636 (2011)
5. J.-J. Liu, Y.-Y. Chen, Z.-N. Mo, G.-X. Tian, A.-H. Tan, Y. Gao, X.-B. Yang, H.-Y. Zhang, Z.-X. Li, Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in adult males, South China. Int. J. Mol. Sci. 14, 19782–19791 (2013)
6. J. Dou, X. Ma, Q. Fang, Y. Hao, R. Yang, F. Wang, J. Zhu, Y. Bao, W. Jia, Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in Chinese men. Clin. Exp. Pharmacol. Physiol. 40, 282–288 (2013)
7. D.H. Sinn, G.Y. Gwak, S.Y. Rhee, J. Cho, H.J. Son, Y.H. Paik, M.S. Choi, J.H. Lee, K.C. Koh, B.C. Yoo, S.W. Paik, Association between serum osteocalcin levels and non-alcoholic fatty liver disease in women. Digestion. 91, 150–157 (2015)
8. B. Zhou, H. Li, L. Xu, W. Zang, S. Wu, H. Sun, Osteocalcin reverses endoplasmic reticulum stress and improves impaired insulin sensitivity secondary to diet-induced obesity through nuclear factor-κB signaling pathway. Endocrinology 154, 1055–1068 (2013)
9. A.A. Gupte, O.M. Sabek, D. Fraga, L.J. Minze, S.K. Nishimoto, J.Z. Liu, S. Afshar, L. Gaber, C.J. Lyon, A.O. Gaber, W.A. Hsueh, Osteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome. Endocrinology 155, 4697–4705 (2014)
10. L.A. Videla, Oxidative stress signaling underlying liver disease and hepatoprotective mechanisms. World J. Hepatol. 1, 72–78 (2009)
11. H. Zhu, K. Itoh, M. Yamamoto, J.L. Zweier, Y. Li, Role of Nrf2 signaling in regulation of antioxidants and phase 2 enzymes in cardiac fibroblasts: protection against reactive oxygen and nitrogen species-induced cell injury. FEBS Lett. 579, 3029–3036 (2005)
12. S. Chowdhry, M.H. Nazmy, P.J. Meakin, A.T. Dinkova-Kostova, S.V. Walsh, T. Tsujita, J.F. Dillon, M.L.J. Ashford, J.D. Hayes, Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic. Biol. Med. 48, 357–371 (2010)
13. C. Wang, Y. Cui, C. Li, Y. Zhang, S. Xu, X. Li, H. Li, X. Zhang, Nrf2 deletion causes “benign” simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet. Lipids Health Dis. 12, 165 (2013)
14. P.J. Meakin, S. Chowdhry, R.S. Sharma, F.B. Ashford, S.V. Walsh, R.J. McCrimmon, A.T. Dinkova-Kostova, J.F. Dillon, J.D. Hayes, M.L.J. Ashford, Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol. Cell. Biol. 34, 3305–3320 (2014)
15. E. Seki, D.A. Brenner, M. Karin, A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 143, 307–320 (2012)
16. D. Ye, F.Y.L. Li, K.S.L. Lam, H. Li, W. Jia, Y. Wang, K. Man, C.M. Lo, X. Li, A. Xu, Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 61, 1058–1067 (2012)
17. J. Folch, M. Lees, G.H. Sloane Stanley, A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226, 497–509 (1957)
18. J. Dou, H. Li, X. Ma, M. Zhang, Q. Fang, M. Nie, Y. Bao, W. Jia, Osteocalcin attenuates high fat diet-induced impairment of endothelium-dependent relaxation through Akt/eNOS-dependent pathway. Cardiovasc. Diabetol. 13, 74 (2014)
19. K. Imajo, M. Yoneda, T. Kessoku, Y. Ogawa, S. Maeda, Y. Sumida, H. Hyogo, Y. Eguchi, K. Wada, A. Nakajima, Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Int. J. Mol. Sci. 14, 21833–21857 (2013)
20. M. Ferron, M.D. McKee, R.L. Levine, P. Ducy, G. Karsenty, Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone 50, 568–575 (2012)
21. M. Ferron, E. Hinoi, G. Karsenty, P. Ducy, Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl. Acad. Sci. 105, 5266–5270 (2008)
22. P. Tessari, A. Coracina, A. Cosma, A. Tiengo, Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 19, 291–302 (2009)
23. J.A. Lawson, J. Rokach, G.A. FitzGerald, Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem. 274, 24441–24444 (1999)
24. D. Ye, Y. Wang, H. Li, W. Jia, K. Man, C.M. Lo, Y. Wang, K.S.L. Lam, A. Xu, FGF21 protects against acetaminophen-induced hepatotoxicity by potentiating PGC-1α-mediated antioxidant capacity in mice. Hepatology 60, 977–989 (2014)
25. A.A. Gupte, C.J. Lyon, W.A. Hsueh, Nuclear factor (erythroid-derived 2)-like-2 factor (Nrf2), a key regulator of the antioxidant response to protect against atherosclerosis and nonalcoholic steatohepatitis. Curr. Diabetes Rep. 13, 362–371 (2013)
26. S. Shin, J. Wakabayashi, M.S. Yates, N. Wakabayashi, P.M. Dolan, S. Aja, K.T. Liby, M.B. Sporn, M. Yamamoto, T.W. Kensler, Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur. J. Pharmacol. 620, 138–144 (2009)
27. M.J. Czaja, JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol. Metab. 21, 707–713 (2010)
28. J. Hirosumi, G. Tuncman, L. Chang, C.Z. Görgün, K.T. Uysal, K. Maeda, M. Karin, G.S. Hotamisligil, A central role for JNK in obesity and insulin resistance. Nature 420, 333–336 (2002)
29. J.M. Schattenberg, R. Singh, Y. Wang, J.H. Lefkowitch, R.M. Rigoli, P.E. Scherer, M.J. Czaja, JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43, 163–172 (2006)
30. R. Singh, Y. Wang, Y. Xiang, K.E. Tanaka, W.A. Gaarde, M.J. Czaja, Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 49, 87–96 (2009)
31. H. Kamata, S.-I. Honda, S. Maeda, L. Chang, H. Hirata, M. Karin, Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120, 649–661 (2005)
32. T. Fujiwara, S. Kanazawa, R. Ichibori, T. Tanigawa, T. Magome, K. Shingaki, S. Miyata, M. Tohyama, K. Hosokawa, L-Arginine stimulates fibroblast proliferation through the GPRC6A-ERK1/2 and PI3K/Akt pathway. PLoS One 9, e92168 (2014)
33. L. De Toni, V. De Filippis, S. Tescari, M. Ferigo, A. Ferlin, V. Scattolini, A. Avogaro, R. Vettor, C. Foresta, Uncarboxylated osteocalcin stimulates 25-hydroxy vitamin D production in leydig cell line through a GPRC6a-dependent pathway. Endocrinology 155, 4266–4274 (2014)
34. A. Mizokami, Y. Yasutake, S. Higashi, T. Kawakubo-Yasukochi, S. Chishaki, I. Takahashi, H. Takeuchi, M. Hirata, Oral administration of osteocalcin improves glucose utilization by stimulating glucagon-like peptide-1 secretion. Bone 69C, 68–79 (2014)
35. M. Pi, Y. Wu, L.D. Quarles, GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo. J. Bone Miner. Res. 26, 1680–1683 (2011)